Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.

Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB

International journal of chronic obstructive pulmonary disease22 Feb 2022Cited by 40 (Europe PMC)

PMID35237033PMCIDPMC8882670DOI10.2147/copd.s350133PepBankPUB-35237033

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide 3.0 mg caused significant weight loss versus placebo over 40 weeks.
In plain wordsIn people with obesity and COPD, those on liraglutide lost more weight than those on placebo over 40 weeks.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 40
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703301
02HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide increased forced vital capacity versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide raised forced vital capacity more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseForced vital capacity (FVC)
Study
n = 40
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703302
03HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide increased carbon monoxide diffusion capacity versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide raised the lungs' gas transfer capacity more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseCarbon monoxide diffusion capacity
Study
n = 40
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703303
04HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide improved the CAT score versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide improved the COPD symptom score more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseCOPD assessment test (CAT) score
Study
n = 40
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703304
05HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide did not significantly change FEV1 versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide did not change forced expiratory volume in one second compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeFEV1
Study
n = 40
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
We found no significant changes in forced expiratory volume in one second (FEV₁), FEV₁/FVC, or 6-min walking distance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703305
06HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide did not significantly change the FEV1/FVC ratio versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide did not change the FEV1/FVC ratio compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeFEV1/FVC
Study
n = 40
Comparator
Placebo
Outcome group
Respiratory function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
We found no significant changes in forced expiratory volume in one second (FEV₁), FEV₁/FVC, or 6-min walking distance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703306
07HumanRandomized controlled trialEfficacy outcome
In people with obesity and COPD, liraglutide did not significantly change 6-min walking distance versus placebo.
In plain wordsIn people with obesity and COPD, liraglutide did not change how far people could walk in 6 minutes compared with placebo.
Peptide
Liraglutide
Outcome
No significant change6-min walking distance
Study
n = 40
Comparator
Placebo
Outcome group
Exercise and physical function · Respiratory
Studied dose
3.0 mg · subcutaneous · 40 weeksAs given in this study (human).
Source sentences
Summary
We found no significant changes in forced expiratory volume in one second (FEV₁), FEV₁/FVC, or 6-min walking distance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks.
Report a problemFND-3523703307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.